title: Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
abstract: OBJECTIVE
  The aim of the present study was to invesitigate the impact of significant clinico-pathological prognostic factors on survival rates and to identify factors predictive of poor outcome in patients with ovarian carcinoma.
  
  
  METHODS
  A retrospective chart review of 74 women with pathologically proven ovarian carcinoma who were treated between January 2006 and April 2011 was performed. Patients were investigated with respect to survival to find the possible effects of age, gravida, parity, menstruel condition, pre-operative Ca-125, treatment period, cytologic washings, presence of ascites, tumor histology, stage and grade, maximal tumor diameter, adjuvan chemotherapy and cytoreductive success. Also 55 ovarian carcinoma patients were investigated with respect to prognostic factors for early 2-year survival.
  
  
  RESULTS
  The two-year survival rate was 69% and the 5-year survival rate was 25.5% for the whole study population. Significant factors for 2-year survival were preoperative CA-125 level, malignant cytology and FIGO clinical stage. Significant factors for 5-year survival were age, preoperative CA-125 level, residual tumor, lymph node metastases, histologic type of tumor, malignant cytology and FIGO clinical stage. Logistic regression revealed that independent prognostic factors of 5-year survival were patient age, lymph node metastasis and malignant cytology.
  
  
  CONCLUSIONS
  We consider quality registries with prospectively collected data to be one important tool in monitoring treatment effects in population-based cancer research.
authors.affiliation: Obstetrics and Gynecology, Ataturk Training and Research Hospital, Izmir, Turkey E-mail : burcuharmandar@gmail.com.
authors.forename: Sevim Kalsen
authors.initials: SK
authors.lastname: Arikan
authors.forename: Burcu
authors.initials: B
authors.lastname: Kasap
authors.forename: Hakan
authors.initials: H
authors.lastname: Yetimalar
authors.forename: Askin
authors.initials: A
authors.lastname: Yildiz
authors.forename: Derya Kilic
authors.initials: DK
authors.lastname: Sakarya
authors.forename: Sumeyra
authors.initials: S
authors.lastname: Tatar
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D002288:Adenocarcinoma, Mucinous / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate